

Contact

Merck KGaA, Darmstadt, Germany
Investor Relations
Frankfurter Strasse 250
64293 Darmstadt
Germany
Phone: +49 6151 72 3321
e-mail: investor.relations@emdgroup.com
www.emdgroup.com

WKN: 659990
ISIN: DE0006599905
Ticker Symbol: MRK

Financial Statements Q1 2024 – Q2 2025

Content

1 Income statements

- 1.1 Group, quarterly
- 1.2 Life Science, quarterly
- 1.3 Healthcare, quarterly
- 1.4 Electronics, quarterly
- 1.5 Corporate/Others, quarterly
- 1.6 Financial result, quarterly

2 Cash flow statement

3 Balance sheet

Net sales/Net sales growth by business sector Merck KGaA, Darmstadt, Germany

Classification: CONFIDENTIAL

| € million | 2024 | | | | | | | | 2025 | | | | | | | |
|---------------------|----------------|----------------|-----------------|----------------|-----------------|----------------|-----------------|-----------------|----------------|----------------|-----------------|----|----|----|----|----|
| | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| Group | 5,119.8 | 5,352.2 | 10,472.0 | 5,266.1 | 15,738.0 | 5,417.7 | 10,683.8 | 21,155.8 | 5,280.1 | 5,254.9 | 10,535.0 | | | | | |
| YoY Δ | -173.2 | 49.8 | -123.4 | 93.0 | -30.4 | 193.2 | 286.2 | 162.8 | 160.3 | -97.3 | 63.0 | | | | | |
| Acquisitions Δ | -0.6 | -2.2 | -2.7 | -1.9 | -4.6 | 20.0 | 18.1 | 15.3 | 12.3 | 22.7 | 35.1 | | | | | |
| Fx Δ | -108.3 | -38.4 | -146.7 | -102.6 | -249.3 | -27.6 | -130.2 | -277.0 | 18.5 | -226.7 | -208.2 | | | | | |
| Organic Δ | -64.3 | 90.4 | 26.1 | 197.5 | 223.6 | 200.9 | 398.4 | 424.5 | 129.5 | 106.6 | 236.2 | | | | | |
| Life Science | 2,143.7 | 2,258.1 | 4,401.8 | 2,209.7 | 6,611.5 | 2,304.5 | 4,514.2 | 8,916.0 | 2,217.8 | 2,266.8 | 4,484.5 | | | | | |
| YoY Δ | -343.1 | -95.5 | -438.5 | 18.8 | -419.7 | 55.2 | 74.0 | -364.5 | 74.1 | 8.7 | 82.8 | | | | | |
| Acquisitions Δ | | | | | | 6.7 | 6.7 | 6.7 | 6.4 | 6.3 | 12.7 | | | | | |
| Fx Δ | -30.4 | -8.5 | -38.9 | -27.2 | -66.1 | 4.8 | -22.5 | -61.3 | 13.0 | -81.0 | -68.0 | | | | | |
| Organic Δ | -312.7 | -87.0 | -399.7 | 46.1 | -353.6 | 43.7 | 89.8 | -309.9 | 54.6 | 83.5 | 138.1 | | | | | |
| Healthcare | 2,047.7 | 2,136.7 | 4,184.4 | 2,133.4 | 6,317.8 | 2,136.7 | 4,270.1 | 8,454.5 | 2,114.1 | 2,101.7 | 4,215.8 | | | | | |
| YoY Δ | 142.2 | 87.2 | 229.4 | 67.1 | 296.5 | 104.8 | 171.9 | 401.3 | 66.4 | -35.1 | 31.4 | | | | | |
| Acquisitions Δ | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | |
| Fx Δ | -49.3 | -21.8 | -71.2 | -62.0 | -133.2 | -31.1 | -93.1 | -164.3 | -3.3 | -111.7 | -115.0 | | | | | |
| Organic Δ | 191.5 | 109.1 | 300.6 | 129.1 | 429.7 | 135.9 | 265.0 | 565.6 | 69.7 | 76.7 | 146.4 | | | | | |
| Electronics | 928.4 | 957.4 | 1,885.8 | 923.0 | 2,808.8 | 976.5 | 1,899.5 | 3,785.3 | 948.2 | 886.5 | 1,834.7 | | | | | |
| YoY Δ | 27.7 | 58.1 | 85.8 | 7.1 | 92.8 | 33.3 | 40.3 | 126.1 | 19.9 | -70.9 | -51.1 | | | | | |
| Acquisitions Δ | -0.6 | -2.2 | -2.7 | -1.9 | -4.6 | 13.3 | 11.4 | 8.6 | 6.0 | 16.4 | 22.4 | | | | | |
| Fx Δ | -28.6 | -8.1 | -36.7 | -13.4 | -50.1 | -1.3 | -14.7 | -51.3 | 8.7 | -33.9 | -25.2 | | | | | |
| Organic Δ | 56.8 | 68.3 | 125.2 | 22.3 | 147.5 | 21.3 | 43.6 | 168.8 | 5.2 | -53.5 | -48.3 | | | | | |

| Group | 2024 | | | | | | | |
|---------------------|--------|-------|-------|-------|-------|-------|-------|-------|
| | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| YoY % | -3.3% | 0.9% | -1.2% | 1.8% | -0.2% | 3.7% | 2.8% | 0.8% |
| Acquisitions % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.4% | 0.2% | 0.1% |
| Fx % | -2.0% | -0.7% | -1.4% | -2.0% | -1.6% | -0.5% | -1.3% | -1.3% |
| Organic % | -1.2% | 1.7% | 0.2% | 3.8% | 1.4% | 3.8% | 3.8% | 2.0% |
| Life Science | | | | | | | | |
| YoY % | -13.8% | -4.1% | -9.1% | 0.9% | -6.0% | 2.5% | 1.7% | -3.9% |
| Acquisitions % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.2% | 0.1% |
| Fx % | -1.2% | -0.4% | -0.8% | -1.2% | -0.9% | 0.2% | -0.5% | -0.7% |
| Organic % | -12.6% | -3.7% | -8.3% | 2.1% | -5.0% | 1.9% | 2.0% | -3.3% |
| Healthcare | | | | | | | | |
| YoY % | 7.5% | 4.3% | 5.8% | 3.2% | 4.9% | 5.2% | 4.2% | 5.0% |
| Acquisitions % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Fx % | -2.6% | -1.1% | -1.8% | -3.0% | -2.2% | -1.5% | -2.3% | -2.0% |
| Organic % | 10.1% | 5.3% | 7.6% | 6.2% | 7.1% | 6.7% | 6.5% | 7.0% |
| Electronics | | | | | | | | |
| YoY % | 3.1% | 6.5% | 4.8% | 0.8% | 3.4% | 3.5% | 2.2% | 3.4% |
| Acquisitions % | -0.1% | -0.2% | -0.2% | -0.2% | -0.2% | 1.4% | 0.6% | 0.2% |
| Fx % | -3.2% | -0.9% | -2.0% | -1.5% | -1.8% | -0.1% | -0.8% | -1.4% |
| Organic % | 6.3% | 7.6% | 7.0% | 2.4% | 5.4% | 2.3% | 2.3% | 4.6% |

EBITDA pre by business sector Merck KGaA, Darmstadt, Germany

| € million | 2024 | | | | | | | | 2025 | | | | | | | |
|-------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----|----|----|----|----|
| | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| Group | 1,453.9 | 1,508.9 | 2,962.8 | 1,617.7 | 4,580.6 | 1,491.1 | 3,108.8 | 6,071.6 | 1,535.1 | 1,462.4 | 2,997.5 | | | | | |
| % Margin | 28.4% | 28.2% | 28.3% | 30.7% | 29.1% | 27.5% | 29.1% | 28.7% | 29.1% | 27.8% | 28.5% | | | | | |
| YoY Δ | -133.1 | -44.3 | -177.4 | 172.1 | -5.4 | 198.0 | 370.1 | 192.7 | 81.2 | -46.5 | 34.7 | | | | | |
| Acquisitions Δ | 0.0 | -0.1 | -0.1 | -0.2 | -0.3 | -2.8 | -2.9 | -3.0 | -6.7 | -7.0 | -13.7 | | | | | |
| Fx Δ | -50.7 | -32.0 | -82.8 | -71.8 | -154.6 | -54.3 | -126.1 | -208.9 | 3.5 | -108.5 | -105.0 | | | | | |
| Organic Δ | -82.4 | -12.2 | -94.6 | 244.1 | 149.5 | 255.1 | 499.2 | 404.6 | 84.4 | 69.0 | 153.4 | | | | | |
| Life Science | 611.2 | 654.7 | 1,265.9 | 646.4 | 1,912.4 | 676.8 | 1,323.3 | 2,589.2 | 622.3 | 646.1 | 1,268.4 | | | | | |
| % Margin | 28.5% | 29.0% | 28.8% | 29.3% | 28.9% | 29.4% | 29.3% | 29.0% | 28.1% | 28.5% | 28.3% | | | | | |
| YoY Δ | -289.4 | -57.2 | -346.6 | 31.3 | -315.3 | 84.8 | 116.1 | -230.5 | 11.1 | -8.6 | 2.5 | | | | | |
| Acquisitions Δ | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -5.2 | -5.2 | -5.2 | -4.4 | -6.0 | -10.4 | | | | | |
| Fx Δ | -16.6 | -13.6 | -30.2 | -12.1 | -42.4 | -4.8 | -16.9 | -47.1 | -3.5 | -27.0 | -30.5 | | | | | |
| Organic Δ | -272.8 | -43.6 | -316.4 | 43.4 | -272.9 | 94.8 | 138.2 | -178.1 | 19.0 | 24.5 | 43.5 | | | | | |
| Healthcare | 708.0 | 719.8 | 1,427.8 | 835.7 | 2,263.5 | 731.2 | 1,566.9 | 2,994.6 | 795.8 | 782.8 | 1,578.6 | | | | | |
| % Margin | 34.6% | 33.7% | 34.1% | 39.2% | 35.8% | 34.2% | 36.7% | 35.4% | 37.6% | 37.2% | 37.4% | | | | | |
| YoY Δ | 118.4 | 16.2 | 134.6 | 150.3 | 284.9 | 166.7 | 317.0 | 451.6 | 87.8 | 63.0 | 150.8 | | | | | |
| Acquisitions Δ | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | |
| Fx Δ | -48.6 | -16.4 | -65.0 | -34.8 | -99.8 | -26.4 | -61.1 | -126.1 | 5.3 | -81.3 | -76.0 | | | | | |
| Organic Δ | 167.0 | 32.6 | 199.6 | 185.1 | 384.7 | 193.0 | 378.1 | 577.7 | 82.5 | 144.3 | 226.8 | | | | | |
| Electronics | 236.6 | 255.3 | 491.9 | 235.2 | 727.1 | 242.5 | 477.7 | 969.6 | 244.3 | 133.6 | 377.9 | | | | | |
| % Margin | 25.5% | 26.7% | 26.1% | 25.5% | 25.9% | 24.8% | 25.2% | 25.6% | 25.8% | 15.1% | 20.6% | | | | | |
| YoY Δ | -0.7 | -6.5 | -7.2 | 27.4 | 20.2 | 36.5 | 63.8 | 56.6 | 7.7 | -121.6 | -114.0 | | | | | |
| Acquisitions Δ | 0.0 | -0.1 | -0.1 | -0.2 | -0.3 | 2.5 | 2.4 | 2.3 | -2.2 | -1.1 | -3.3 | | | | | |
| Fx Δ | -10.0 | 1.7 | -8.3 | -3.6 | -11.9 | 3.1 | -0.5 | -8.8 | 5.1 | -15.0 | -9.9 | | | | | |
| Organic Δ | 9.3 | -8.1 | 1.2 | 31.1 | 32.3 | 30.8 | 61.9 | 63.1 | 4.7 | -105.5 | -100.8 | | | | | |
| Corporate/Others | -101.9 | -120.8 | -222.8 | -99.6 | -322.4 | -159.4 | -259.1 | -481.8 | -127.3 | -100.2 | -227.5 | | | | | |
| YoY Δ | 38.6 | 3.1 | 41.7 | -36.9 | 4.8 | -89.9 | -126.8 | -85.1 | -25.4 | 20.6 | -4.7 | | | | | |

| € million | 2024 | | | | | | | |
|-------------------------|--------|-------|--------|-------|--------|--------|-------|-------|
| | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| YoY % | -8.4% | -2.9% | -5.7% | 11.9% | -0.1% | 15.3% | 13.5% | 3.3% |
| Acquisitions % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -0.2% | -0.1% | -0.1% |
| Fx % | -3.2% | -2.1% | -2.6% | -5.0% | -3.4% | -4.2% | -4.6% | -3.6% |
| Organic % | -5.2% | -0.8% | -3.0% | 16.9% | 3.3% | 19.7% | 18.2% | 6.9% |
| Life Science | | | | | | | | |
| YoY % | -32.1% | -8.0% | -21.5% | 5.1% | -14.2% | 14.3% | 9.6% | -8.2% |
| Acquisitions % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -0.9% | -0.4% | -0.2% |
| Fx % | -1.8% | -1.9% | -1.9% | -2.0% | -1.9% | -0.8% | -1.4% | -1.7% |
| Organic % | -30.3% | -6.1% | -19.6% | 7.1% | -12.3% | 16.0% | 11.4% | -6.3% |
| Healthcare | | | | | | | | |
| YoY % | 20.1% | 2.3% | 10.4% | 21.9% | 14.4% | 29.5% | 25.4% | 17.8% |
| Acquisitions % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Fx % | -8.2% | -2.3% | -5.0% | -5.1% | -5.0% | -4.7% | -4.9% | -5.0% |
| Organic % | 28.3% | 4.6% | 15.4% | 27.0% | 19.4% | 34.2% | 30.3% | 22.7% |
| Electronics | | | | | | | | |
| YoY % | -0.3% | -2.5% | -1.4% | 13.2% | 2.9% | 17.7% | 15.4% | 6.2% |
| Acquisitions % | 0.0% | 0.0% | 0.0% | -0.1% | 0.0% | 1.2% | 0.6% | 0.2% |
| Fx % | -4.2% | 0.7% | -1.7% | -1.7% | -1.7% | 1.5% | -0.1% | -1.0% |
| Organic % | 3.9% | -3.1% | 0.2% | 15.0% | 4.6% | 14.9% | 15.0% | 6.9% |
| Corporate/Others | | | | | | | | |
| YoY % | -27.5% | -2.5% | -15.8% | 58.8% | -1.5% | 129.3% | 95.9% | 21.4% |

Due to rounding the sum of individual values may not add up to totals presented.

Reconciliation to EBITDA, EBITDA pre and EPS pre

Classification: CONFIDENTIAL

| Group € million | 2024 | | | | | | | | 2025 | | | | | | | | Change YoY | | | | | | | | | | | | | | | | |
|----------------------------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----|----|----|----|----|------------|----|----|----|----|----|----|----|--|--------|---------|--------|---------|---------|---------|---------|---------|
| | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | | | | | | | | | |
| a) Reconciliation to EBITDA and EBITDA pre | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| EBITDA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| EBIT | 931.3 | 792.3 | 1,723.6 | 1,097.1 | 2,820.7 | 824.2 | 1,921.3 | 3,644.9 | 1,005.6 | 891.0 | 1,896.6 | | | | | | | | | | | | | | | 8.0% | 12.4% | 10.0% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Depreciation and amortization | 453.5 | 680.1 | 1,133.6 | 449.3 | 1,582.9 | 550.8 | 1,000.1 | 2,133.8 | 473.5 | 456.7 | 930.2 | | | | | | | | | | | | | | | 4.4% | -32.8% | -17.9% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Regular depreciation and amortization* | 257.6 | 265.6 | 523.2 | 269.8 | 793.1 | 298.6 | 568.5 | 1,091.7 | 280.7 | 273.8 | 554.5 | | | | | | | | | | | | | | | 9.0% | 3.1% | 6.0% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Impairments not adjusted | 9.2 | 10.6 | 19.8 | 8.7 | 28.6 | 21.7 | 30.5 | 50.3 | 17.3 | -3.1 | 14.2 | | | | | | | | | | | | | | | 87.7% | n.m. | -28.4% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Amortization of purchased intangible assets | 186.2 | 181.7 | 367.9 | 168.8 | 536.7 | 177.6 | 346.5 | 714.4 | 173.3 | 159.4 | 332.8 | | | | | | | | | | | | | | | -6.9% | -12.3% | -9.5% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Impairments (net)** | 0.5 | 222.2 | 222.7 | 1.9 | 224.6 | 52.8 | 54.7 | 277.4 | 2.1 | 26.6 | 28.7 | | | | | | | | | | | | | | | 343.0% | -88.0% | -87.1% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Total | 1,384.8 | 1,472.5 | 2,857.3 | 1,546.4 | 4,403.7 | 1,375.0 | 2,921.4 | 5,778.7 | 1,479.1 | 1,347.7 | 2,826.8 | | | | | | | | | | | | | | | 6.8% | -8.5% | -1.1% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Adjustments | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Acquisition costs | 2.5 | 0.4 | 2.9 | 5.5 | 8.4 | 17.2 | 22.7 | 25.6 | 2.1 | 19.4 | 21.5 | | | | | | | | | | | | | | | -16.8% | >1,000% | 644.4% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Restructuring costs | 44.6 | 34.1 | 78.7 | 37.2 | 115.9 | 27.6 | 64.8 | 143.5 | 31.0 | 17.3 | 48.4 | | | | | | | | | | | | | | | -30.4% | -49.2% | -38.5% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Integration costs/IT costs | 17.4 | 21.2 | 38.6 | 21.7 | 60.2 | 42.4 | 64.1 | 102.7 | 17.0 | 29.3 | 46.3 | | | | | | | | | | | | | | | -2.2% | 38.3% | 20.1% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Gain (-)/ losses (+) on the divestment of businesses | -4.8 | -51.7 | -56.5 | 0.3 | -56.2 | 9.7 | 10.0 | -46.5 | 5.3 | 33.4 | 38.7 | | | | | | | | | | | | | | | n.m. | n.m. | n.m. | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Other one-time costs | 9.4 | 32.5 | 41.9 | 6.6 | 48.5 | 19.1 | 25.7 | 67.6 | 0.6 | 15.3 | 15.9 | | | | | | | | | | | | | | | -93.1% | -53.1% | -62.0% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Total | 69.1 | 36.5 | 105.5 | 71.4 | 176.9 | 116.0 | 187.4 | 292.9 | 56.0 | 114.7 | 170.7 | | | | | | | | | | | | | | | -18.9% | 214.6% | 61.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| EBITDA pre | 1,453.9 | 1,508.9 | 2,962.8 | 1,617.7 | 4,580.6 | 1,491.1 | 3,108.8 | 6,071.6 | 1,535.1 | 1,462.4 | 2,997.5 | | | | | | | | | | | | | | | 5.6% | -3.1% | 1.2% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| b) Reconciliation to EPS pre | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 1) Reconciliation starting from EBITDA pre | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| EBITDA pre | 1,453.9 | 1,508.9 | 2,962.8 | 1,617.7 | 4,580.6 | 1,491.1 | 3,108.8 | 6,071.6 | 1,535.1 | 1,462.4 | 2,997.5 | | | | | | | | | | | | | | | 5.6% | -3.1% | 1.2% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Regular depreciation and amortization* | -257.6 | -265.6 | -523.2 | -269.8 | -793.1 | -298.6 | -568.5 | -1,091.7 | -280.7 | -273.8 | -554.5 | | | | | | | | | | | | | | | 9.0% | 3.1% | 6.0% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Impairments not adjusted | -9.2 | -10.6 | -19.8 | -8.7 | -28.6 | -21.7 | -30.5 | -50.3 | -17.3 | 3.1 | -14.2 | | | | | | | | | | | | | | | 87.7% | n.m. | -28.4% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Financial result | -32.2 | -7.2 | -39.4 | -54.1 | -93.5 | -15.0 | -69.1 | -108.5 | -49.8 | -61.8 | -111.6 | | | | | | | | | | | | | | | 54.4% | 764.2% | 183.3% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Adjustments within Financial result | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | | | | | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Profit before income tax pre | 1,154.8 | 1,225.5 | 2,380.4 | 1,285.1 | 3,665.4 | 1,155.7 | 2,440.7 | 4,821.1 | 1,187.3 | 1,129.8 | 2,317.2 | | | | | | | | | | | | | | | 2.8% | -7.8% | -2.7% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Income tax pre | -254.1 | -269.6 | -523.7 | -282.7 | -806.4 | -254.3 | -537.0 | -1,060.6 | -261.2 | -248.6 | -509.8 | | | | | | | | | | | | | | | 2.8% | -7.8% | -2.7% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| underlying tax rate | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | | | | | | | | | | | | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-controlling interest | -5.2 | 2.0 | -3.3 | -2.9 | -6.1 | -3.1 | -5.9 | -9.2 | -2.6 | -3.3 | -5.8 | | | | | | | | | | | | | | | -50.7% | n.m. | 78.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Net income pre | 895.6 | 957.9 | 1,853.4 | 999.5 | 2,852.9 | 898.4 | 1,897.8 | 3,751.3 | 923.6 | 878.0 | 1,801.6 | | | | | | | | | | | | | | | 3.1% | -8.3% | -2.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| EPS pre in €*** | 2.06 | 2.20 | 4.26 | 2.30 | 6.56 | 2.07 | 4.37 | 8.63 | 2.12 | 2.02 | 4.14 | | | | | | | | | | | | | | | 2.9% | -8.2% | -2.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| 2) Reconciliation starting from Profit before tax | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Profit before income tax | 899.1 | 785.2 | 1,684.3 | 1,043.0 | 2,727.3 | 809.2 | 1,852.2 | 3,536.5 | 955.8 | 829.2 | 1,785.0 | | | | | | | | | | | | | | | 6.3% | 5.6% | 6.0% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Amortization of purchased intangible assets | 186.2 | 181.7 | 367.9 | 168.8 | 536.7 | 177.6 | 346.5 | 714.4 | 173.3 | 159.4 | 332.8 | | | | | | | | | | | | | | | -6.9% | -12.3% | -9.5% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Impairments** | 0.5 | 222.2 | 222.7 | 1.9 | 224.6 | 52.8 | 54.7 | 277.4 | 2.1 | 26.6 | 28.7 | | | | | | | | | | | | | | | 343.0% | -88.0% | -87.1% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Adjustments | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Acquisition costs | 2.5 | 0.4 | 2.9 | 5.5 | 8.4 | 17.2 | 22.7 | 25.6 | 2.1 | 19.4 | 21.5 | | | | | | | | | | | | | | | -16.8% | >1,000% | 644.4% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Restructuring costs | 44.6 | 34.1 | 78.7 | 37.2 | 115.9 | 27.6 | 64.8 | 143.5 | 31.0 | 17.3 | 48.4 | | | | | | | | | | | | | | | -30.4% | -49.2% | -38.5% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Integration costs/IT costs | 17.4 | 21.2 | 38.6 | 21.7 | 60.2 | 42.4 | 64.1 | 102.7 | 17.0 | 29.3 | 46.3 | | | | | | | | | | | | | | | -2.2% | 38.3% | 20.1% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Gain (-)/ losses (+) on the divestment of businesses | -4.8 | -51.7 | -56.5 | 0.3 | -56.2 | 9.7 | 10.0 | -46.5 | 5.3 | 33.4 | 38.7 | | | | | | | | | | | | | | | n.m. | n.m. | n.m. | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Other one-time costs | 9.4 | 32.5 | 41.9 | 6.6 | 48.5 | 19.1 | 25.7 | 67.6 | 0.6 | 15.3 | 15.9 | | | | | | | | | | | | | | | -93.1% | -53.1% | -62.0% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Adjustments within Financial result | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | | | | | | | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total adjustments | 69.1 | 36.5 | 105.5 | 71.4 | 176.9 | 116.0 | 187.4 | 292.9 | 56.0 | 114.7 | 170.7 | | | | | | | | | | | | | | | -18.9% | 214.6% | 61.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Profit before income tax pre | 1,154.8 | 1,225.5 | 2,380.4 | 1,285.1 | 3,665.4 | 1,155.7 | 2,440.7 | 4,821.1 | 1,187.3 | 1,129.8 | 2,317.2 | | | | | | | | | | | | | | | 2.8% | -7.8% | -2.7% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Income tax pre | -254.1 | -269.6 | -523.7 | -282.7 | -806.4 | -254.3 | -537.0 | -1,060.6 | -261.2 | -248.6 | -509.8 | | | | | | | | | | | | | | | 2.8% | -7.8% | -2.7% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| underlying tax rate | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | 22.0% | | | | | | | | | | | | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total costs excluded from Net income | 201.3 | 350.5 | 551.8 | 190.7 | 742.5 | 232.2 | 422.8 | 974.7 | 188.2 | 225.8 | 414.1 | | | | | | | | | | | | | | | -6.5% | -35.6% | -25.0% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Total costs excluded from EPS in€ | 0.46 | 0.81 | 1.27 | 0.44 | 1.71 | 0.53 | 0.97 | 2.24 | 0.43 | 0.52 | 0.95 | | | | | | | | | | | | | | | -6.5% | -35.8% | -25.2% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Non-controlling interest | -5.2 | 2.0 | -3.3 | -2.9 | -6.1 | -3.1 | -5.9 | -9.2 | -2.6 | -3.3 | -5.8 | | | | | | | | | | | | | | | -50.7% | n.m. | 78.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Net income pre | 895.6 | 957.9 | 1,853.4 | 999.5 | 2,852.9 | 898.4 | 1,897.8 | 3,751.3 | 923.6 | 878.0 | 1,801.6 | | | | | | | | | | | | | | | 3.1% | -8.3% | -2.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| EPS pre in €*** | 2.06 | 2.20 | 4.26 | 2.30 | 6.56 | 2.07 | 4.37 | 8.63 | 2.12 | 2.02 | 4.14 | | | | | | | | | | | | | | | 2.9% | -8.2% | -2.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |

Number of theoretical shares in million: 434.8, 434.8, 434.8, 434.8, 434.8, 434.8, 434.8, 434.8, 434.8, 434.8, 434.8

Due to rounding the sum of individual values may not add up to totals presented

* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

** Only reflects impairments classified as adjustments

*** For continuing operations

Income Statement Merck KGaA, Darmstadt, Germany

Life Science

€ million

Classification: CONFIDENTIAL

| | 2024 | | | | | | | | 2025 | | | | | | | | Change YoY | | | | | | | | | | | | | | | |
|-------------------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----|----|----|----|----|------------|----|----|----|----|----|----|-------|--------|---------|---------|---------|---------|---------|---------|---------|
| | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | | | | | | | | |
| Net sales | 2,143.7 | 2,258.1 | 4,401.8 | 2,209.7 | 6,611.5 | 2,304.5 | 4,514.2 | 8,916.0 | 2,217.8 | 2,266.8 | 4,484.5 | | | | | | | | | | | | | | 3.5% | 0.4% | 1.9% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Cost of sales | -987.6 | -1,041.9 | -2,029.5 | -1,008.2 | -3,037.6 | -1,112.4 | -2,120.6 | -4,150.1 | -1,039.9 | -1,079.1 | -2,118.9 | | | | | | | | | | | | | | 5.3% | 3.6% | 4.4% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| thereof amortization of intangible assets | -7.1 | -6.9 | -14.0 | -5.5 | -19.5 | -11.7 | -17.2 | -31.2 | -8.0 | -5.9 | -13.9 | | | | | | | | | | | | | | 12.8% | -14.3% | -0.5% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Gross profit | 1,156.2 | 1,216.2 | 2,372.3 | 1,201.5 | 3,573.8 | 1,192.1 | 2,393.6 | 4,765.9 | 1,177.9 | 1,187.7 | 2,365.6 | | | | | | | | | | | | | | 1.9% | -2.3% | -0.3% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| <i>in % of net sales</i> | 53.9% | 53.9% | 53.9% | 54.4% | 54.1% | 51.7% | 53.0% | 53.5% | 53.1% | 52.4% | 52.8% | | | | | | | | | | | | | | | | | | | | | |
| SG&A | -683.3 | -749.4 | -1,432.7 | -698.7 | -2,131.5 | -739.9 | -1,438.7 | -2,871.4 | -709.5 | -726.1 | -1,435.5 | | | | | | | | | | | | | | 3.8% | -3.1% | 0.2% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| <i>in % of net sales</i> | 31.9% | 33.2% | 32.5% | 31.6% | 32.2% | 32.1% | 31.9% | 32.2% | 32.0% | 32.0% | 32.0% | | | | | | | | | | | | | | | | | | | | | |
| Marketing and selling expenses | -550.6 | -566.5 | -1,117.1 | -543.4 | -1,660.5 | -577.1 | -1,120.5 | -2,237.6 | -554.7 | -544.3 | -1,098.9 | | | | | | | | | | | | | | 0.7% | -3.9% | -1.6% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| thereof amortization of intangible assets (M&S) | -98.7 | -99.4 | -198.1 | -92.1 | -290.2 | -94.7 | -186.8 | -385.0 | -95.3 | -88.9 | -184.2 | | | | | | | | | | | | | | -3.4% | -10.6% | -7.0% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Administration expenses | -111.9 | -104.4 | -216.3 | -104.1 | -320.4 | -120.4 | -224.5 | -440.8 | -106.7 | -117.4 | -224.1 | | | | | | | | | | | | | | -4.7% | 12.5% | 3.6% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Impairment losses and reversals (IFRS 9) | -1.0 | -0.1 | -1.1 | -6.2 | -7.3 | 0.4 | -5.8 | -6.9 | -2.0 | -1.9 | -3.9 | | | | | | | | | | | | | | 96.0% | >1,000% | 242.7% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Other operating expenses/income | -19.7 | -78.5 | -98.2 | -45.0 | -143.2 | -42.9 | -87.9 | -186.1 | -46.1 | -62.4 | -108.5 | | | | | | | | | | | | | | 133.6% | -20.5% | 10.5% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Impairments** | 0.0 | -56.0 | -56.0 | 0.0 | -56.0 | -29.8 | -29.8 | -85.8 | 0.0 | -19.2 | -19.2 | | | | | | | | | | | | | | n.m. | -65.7% | -65.7% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Research and development costs | -95.4 | -96.4 | -191.8 | -92.0 | -283.8 | -104.0 | -196.0 | -387.8 | -99.3 | -96.9 | -196.1 | | | | | | | | | | | | | | 4.0% | 0.5% | 2.2% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| <i>in % of net sales</i> | 4.5% | 4.3% | 4.4% | 4.2% | 4.3% | 4.5% | 4.3% | 4.3% | 4.5% | 4.3% | 4.4% | | | | | | | | | | | | | | | | | | | | | |
| thereof amortization of intangible assets (R&D) | -2.1 | -2.1 | -4.2 | -2.1 | -6.2 | -2.7 | -4.8 | -9.0 | -2.8 | -2.7 | -5.5 | | | | | | | | | | | | | | 35.9% | 29.3% | 32.6% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| EBIT | 377.4 | 370.3 | 747.8 | 410.8 | 1,158.6 | 348.2 | 759.0 | 1,506.7 | 369.2 | 364.8 | 734.0 | | | | | | | | | | | | | -2.2% | -1.5% | -1.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% | |
| <i>in % of net sales</i> | 17.6% | 16.4% | 17.0% | 18.6% | 17.5% | 15.1% | 16.8% | 16.9% | 16.6% | 16.1% | 16.4% | | | | | | | | | | | | | | | | | | | | | |
| Depreciation and amortization | 207.4 | 268.5 | 475.9 | 209.7 | 685.6 | 262.8 | 472.5 | 948.4 | 220.8 | 233.0 | 453.8 | | | | | | | | | | | | | | 6.5% | -13.2% | -4.7% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| EBITDA | 584.8 | 638.8 | 1,223.7 | 620.5 | 1,844.2 | 610.9 | 1,231.5 | 2,455.1 | 590.0 | 597.7 | 1,187.7 | | | | | | | | | | | | | | 0.9% | -6.4% | -2.9% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| <i>in % of net sales</i> | 27.3% | 28.3% | 27.8% | 28.1% | 27.9% | 26.5% | 27.3% | 27.5% | 26.6% | 26.4% | 26.5% | | | | | | | | | | | | | | | | | | | | | |
| EBITDA pre | 611.2 | 654.7 | 1,265.9 | 646.4 | 1,912.4 | 676.8 | 1,323.3 | 2,589.2 | 622.3 | 646.1 | 1,268.4 | | | | | | | | | | | | | | 1.8% | -1.3% | 0.2% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| <i>in % of net sales</i> | 28.5% | 29.0% | 28.8% | 29.3% | 28.9% | 29.4% | 29.3% | 29.0% | 28.1% | 28.5% | 28.3% | | | | | | | | | | | | | | | | | | | | | |
| Reconciliation to EBITDA pre | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| EBITDA | 584.8 | 638.8 | 1,223.7 | 620.5 | 1,844.2 | 610.9 | 1,231.5 | 2,455.1 | 590.0 | 597.7 | 1,187.7 | | | | | | | | | | | | | | 0.9% | -6.4% | -2.9% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Adjustments | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| thereof: Cost of Sales | 0.8 | 0.9 | 1.6 | 0.7 | 2.3 | 22.3 | 23.0 | 24.6 | 0.1 | 13.7 | 13.8 | | | | | | | | | | | | | | -88.8% | >1,000% | 750.9% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| thereof: Marketing and selling expenses | 5.3 | 4.0 | 9.3 | -0.8 | 8.5 | 16.4 | 15.6 | 24.8 | 0.9 | 0.6 | 1.5 | | | | | | | | | | | | | | -82.4% | -85.6% | -83.7% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| thereof: Administration expenses | 17.1 | 8.3 | 25.5 | 5.9 | 31.4 | 26.9 | 32.8 | 58.3 | 8.1 | 17.5 | 25.6 | | | | | | | | | | | | | | -52.8% | 111.0% | 0.7% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| thereof: Other operating expenses/income | 2.6 | 2.6 | 5.2 | 20.0 | 25.3 | 0.3 | 20.3 | 25.5 | 23.2 | 16.5 | 39.7 | | | | | | | | | | | | | | 795.2% | 523.9% | 658.1% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| thereof: Research and development | 0.6 | 0.1 | 0.7 | 0.1 | 0.8 | 0.0 | 0.1 | 0.8 | 0.0 | 0.0 | 0.0 | | | | | | | | | | | | | | -97.3% | -98.2% | -97.5% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Total | 26.4 | 15.9 | 42.2 | 25.9 | 68.2 | 65.9 | 91.8 | 134.0 | 32.3 | 48.4 | 80.7 | | | | | | | | | | | | | 22.7% | 204.4% | 91.0% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% | |
| EBITDA pre | 611.2 | 654.7 | 1,265.9 | 646.4 | 1,912.4 | 676.8 | 1,323.3 | 2,589.2 | 622.3 | 646.1 | 1,268.4 | | | | | | | | | | | | | | 1.8% | -1.3% | 0.2% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |

Due to rounding the sum of individual values may not add up to totals presented.

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

Classification: CONFIDENTIAL

| Electronics € million | 2024 | | | | | | | | 2025 | | | | | | | | Change YoY | | | | | | | |
|-------------------------------------------------|--------------|--------------|----------------|--------------|----------------|--------------|----------------|----------------|--------------|--------------|----------------|----|----|----|----|----|------------|----|----|----|----|----|----|----|
| | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| Net sales | 928.4 | 957.4 | 1,885.8 | 923.0 | 2,808.8 | 976.5 | 1,899.5 | 3,785.3 | 948.2 | 886.5 | 1,834.7 | | | | | | | | | | | | | |
| Cost of sales | -580.1 | -572.8 | -1,153.0 | -558.4 | -1,711.4 | -607.5 | -1,165.9 | -2,318.9 | -571.6 | -582.1 | -1,153.7 | | | | | | | | | | | | | |
| thereof amortization of intangible assets | -30.0 | -25.0 | -55.0 | -21.9 | -76.9 | -18.6 | -40.5 | -95.5 | -18.7 | -16.4 | -35.0 | | | | | | | | | | | | | |
| Gross profit | 348.3 | 384.6 | 732.8 | 364.5 | 1,097.4 | 369.0 | 733.6 | 1,466.4 | 376.7 | 304.3 | 681.0 | | | | | | | | | | | | | |
| <i>in % of net sales</i> | 37.5% | 40.2% | 38.9% | 39.5% | 39.1% | 37.8% | 38.6% | 38.7% | 39.7% | 34.3% | 37.1% | | | | | | | | | | | | | |
| SG&A | -180.0 | -202.5 | -382.5 | -195.3 | -577.8 | -231.9 | -427.2 | -809.7 | -204.2 | -247.9 | -452.0 | | | | | | | | | | | | | |
| <i>in % of net sales</i> | 19.4% | 21.2% | 20.3% | 21.2% | 20.6% | 23.7% | 22.5% | 21.4% | 21.5% | 28.0% | 24.6% | | | | | | | | | | | | | |
| Marketing and selling expenses | -137.7 | -141.9 | -279.6 | -140.5 | -420.0 | -147.7 | -288.1 | -567.7 | -142.5 | -141.5 | -284.0 | | | | | | | | | | | | | |
| thereof amortization of intangible assets (M&S) | -45.6 | -45.5 | -91.1 | -44.5 | -135.5 | -45.4 | -89.9 | -181.0 | -45.6 | -42.7 | -88.3 | | | | | | | | | | | | | |
| Administration expenses | -37.2 | -35.6 | -72.8 | -43.4 | -116.2 | -49.3 | -92.7 | -165.5 | -48.0 | -50.5 | -98.5 | | | | | | | | | | | | | |
| Impairment losses and reversals (IFRS 9) | 0.1 | -1.4 | -1.3 | 0.1 | -1.3 | -0.7 | -0.7 | -2.0 | -0.5 | -0.3 | -0.8 | | | | | | | | | | | | | |
| Other operating expenses/income | -5.2 | -23.6 | -28.8 | -11.6 | -40.3 | -34.2 | -45.7 | -74.5 | -13.2 | -55.6 | -68.7 | | | | | | | | | | | | | |
| Impairments** | -0.5 | -10.5 | -11.0 | -1.7 | -12.7 | -16.2 | -17.9 | -28.9 | -2.1 | -4.2 | -6.3 | | | | | | | | | | | | | |
| Research and development costs | -73.1 | -75.2 | -148.2 | -73.7 | -221.9 | -75.0 | -148.7 | -296.9 | -75.9 | -69.3 | -145.2 | | | | | | | | | | | | | |
| <i>in % of net sales</i> | 7.9% | 7.9% | 7.9% | 8.0% | 7.9% | 7.7% | 7.8% | 7.8% | 8.0% | 7.8% | 7.9% | | | | | | | | | | | | | |
| thereof amortization of intangible assets (R&D) | -1.1 | -1.2 | -2.3 | -1.2 | -3.5 | -2.9 | -4.1 | -6.4 | -1.4 | -1.3 | -2.7 | | | | | | | | | | | | | |
| EBIT | 95.2 | 106.9 | 202.1 | 95.5 | 297.6 | 62.1 | 157.6 | 359.7 | 96.6 | -12.8 | 83.8 | | | | | | | | | | | | | |
| <i>in % of net sales</i> | 10.3% | 11.2% | 10.7% | 10.4% | 10.6% | 6.4% | 8.3% | 9.5% | 10.2% | -1.4% | 4.6% | | | | | | | | | | | | | |
| Depreciation and amortization | 129.8 | 135.2 | 265.0 | 122.8 | 387.8 | 139.1 | 261.9 | 526.9 | 123.7 | 117.5 | 241.1 | | | | | | | | | | | | | |
| EBITDA | 224.9 | 242.1 | 467.0 | 218.4 | 685.4 | 201.2 | 419.6 | 886.6 | 220.2 | 104.7 | 324.9 | | | | | | | | | | | | | |
| <i>in % of net sales</i> | 24.2% | 25.3% | 24.8% | 23.7% | 24.4% | 20.6% | 22.1% | 23.4% | 23.2% | 11.8% | 17.7% | | | | | | | | | | | | | |
| EBITDA pre | 236.6 | 255.3 | 491.9 | 235.2 | 727.1 | 242.5 | 477.7 | 969.6 | 244.3 | 133.6 | 377.9 | | | | | | | | | | | | | |
| <i>in % of net sales</i> | 25.5% | 26.7% | 26.1% | 25.5% | 25.9% | 24.8% | 25.2% | 25.6% | 25.8% | 15.1% | 20.6% | | | | | | | | | | | | | |
| Reconciliation to EBITDA pre | | | | | | | | | | | | | | | | | | | | | | | | |
| EBITDA | 224.9 | 242.1 | 467.0 | 218.4 | 685.4 | 201.2 | 419.6 | 886.6 | 220.2 | 104.7 | 324.9 | | | | | | | | | | | | | |
| Adjustments | | | | | | | | | | | | | | | | | | | | | | | | |
| thereof: Cost of Sales | 3.2 | 4.5 | 7.7 | 1.4 | 9.1 | 7.0 | 8.4 | 16.1 | 4.3 | 5.1 | 9.3 | | | | | | | | | | | | | |
| thereof: Marketing and selling expenses | 0.1 | 0.3 | 0.4 | -0.6 | -0.1 | 2.3 | 1.8 | 2.2 | 3.3 | 5.1 | 8.5 | | | | | | | | | | | | | |
| thereof: Administration expenses | 4.7 | 1.7 | 6.5 | 11.1 | 17.6 | 15.2 | 26.3 | 32.8 | 12.3 | 13.3 | 25.6 | | | | | | | | | | | | | |
| thereof: Other operating expenses/income | 3.4 | 6.5 | 9.9 | 5.0 | 14.9 | 16.2 | 21.1 | 31.0 | 3.8 | 5.2 | 9.0 | | | | | | | | | | | | | |
| thereof: Research and development | 0.2 | 0.2 | 0.4 | 0.0 | 0.4 | 0.5 | 0.5 | 0.9 | 0.3 | 0.3 | 0.6 | | | | | | | | | | | | | |
| Total | 11.7 | 13.2 | 24.9 | 16.9 | 41.7 | 41.3 | 58.2 | 83.0 | 24.1 | 29.0 | 53.0 | | | | | | | | | | | | | |
| EBITDA pre | 236.6 | 255.3 | 491.9 | 235.2 | 727.1 | 242.5 | 477.7 | 969.6 | 244.3 | 133.6 | 377.9 | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |

Due to rounding the sum of individual values may not add up to totals presented.

** Only reflects impairments classified as adjustments.

Income Statement Merck KGaA, Darmstadt, Germany

| Group | 2024 | | | | | | | | | 2025 | | | | | | | | | Change YoY | | | | | | | |
|---------------------------------------------------|-------|-------|--------|-------|--------|-------|--------|--------|-------|-------|--------|----|----|----|----|----|--------|--------|------------|---------|---------|---------|---------|---------|--|--|
| | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | | |
| € million | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Financial result | -32.2 | -7.2 | -39.4 | -54.1 | -93.5 | -15.0 | -69.1 | -108.5 | -49.8 | -61.8 | -111.6 | | | | | | 54.4% | 764.2% | 183.3% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% | | |
| Interest result | -22.1 | -7.5 | -29.6 | -21.8 | -51.4 | -8.9 | -30.7 | -60.3 | -36.2 | -39.4 | -75.6 | | | | | | 63.7% | 427.4% | 155.6% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% | | |
| Interest income | 28.1 | 45.3 | 73.4 | 37.2 | 110.6 | 53.6 | 90.8 | 164.2 | 25.2 | 12.1 | 37.3 | | | | | | -10.3% | -73.3% | -49.2% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% | | |
| Interest expenses | -50.1 | -52.8 | -103.0 | -59.1 | -162.0 | -62.5 | -121.6 | -224.5 | -61.3 | -51.5 | -112.8 | | | | | | 22.3% | -2.5% | 9.6% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% | | |
| Result from financial investments | 7.3 | 11.1 | 18.3 | -19.0 | -0.7 | 2.6 | -16.4 | 1.9 | 1.4 | 0.3 | 1.7 | | | | | | -80.6% | -97.5% | -90.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% | | |
| Currency difference - financing | 6.4 | 8.0 | 14.3 | 1.5 | 15.8 | 11.8 | 13.3 | 27.6 | -0.9 | -10.8 | -11.7 | | | | | | n.m. | n.m. | n.m. | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% | | |
| Interest quota - pensions and other provis | -23.8 | -18.7 | -42.5 | -14.7 | -57.2 | -20.4 | -35.2 | -77.7 | -14.0 | -11.9 | -26.0 | | | | | | -40.9% | -36.3% | -38.9% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% | | |
| Others | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | n.m. | n.m. | n.m. | n.m. | -100.0% | -100.0% | -100.0% | -100.0% | | |

Due to rounding the sum of individual values may not add up to totals presented.

Cash Flow Statement Merck KGaA, Darmstadt, Germany

Group

€ million

Classification: CONFIDENTIAL

| | 2024 | | | | | | | | 2025 | | | | | | | | Change YoY | | | | | | | |
|-----------------------------------------------------------------------------------------------|----------------|---------------|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|---------------|-----------------|----|----|----|----|----|-------------------|---------------|---------------|----------------|----------------|----------------|----------------|----------------|
| | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY | Q1 | Q2 | H1 | Q3 | 9M | Q4 | H2 | FY |
| Profit after tax | 699.5 | 605.4 | 1,304.9 | 811.7 | 2,116.5 | 669.3 | 1,480.9 | 2,785.8 | 737.9 | 655.4 | 1,393.3 | | | | | | 5.5% | 8.3% | 6.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Depreciation/amortization/impairment losses/reversals of impairment losses of tangible assets | 453.5 | 680.1 | 1,133.6 | 449.3 | 1,582.9 | 550.8 | 1,000.1 | 2,133.8 | 473.5 | 456.7 | 930.2 | | | | | | 4.4% | -32.8% | -17.9% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| of intangible assets | 231.5 | 286.1 | 517.5 | 242.6 | 760.2 | 306.3 | 549.0 | 1,066.5 | 255.8 | 263.8 | 519.5 | | | | | | 10.5% | -7.8% | 0.4% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Changes in working capital | 222.0 | 394.1 | 616.1 | 206.6 | 822.7 | 244.5 | 451.1 | 1,067.3 | 217.7 | 193.0 | 410.7 | | | | | | -2.0% | -51.0% | -33.3% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Changes in inventories | -177.4 | -133.7 | -311.2 | -13.1 | -324.2 | 261.6 | 246.5 | -62.6 | -397.4 | -157.9 | -555.3 | | | | | | 124.0% | 31.9% | 84.4% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Changes in trade accounts receivable | -40.9 | 1.1 | -39.8 | 4.0 | -35.9 | 71.6 | 75.6 | 35.7 | -114.0 | -103.5 | -217.5 | | | | | | 178.7% | n.m. | 446.0% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Changes in trade accounts payable/ refund liabilities | -64.0 | -109.5 | -173.6 | 78.1 | -95.5 | 174.6 | 252.7 | 79.1 | -297.1 | -79.0 | -376.1 | | | | | | 363.8% | -27.9% | 116.6% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Changes in provisions | -72.5 | -25.3 | -97.7 | -95.1 | -192.9 | 15.4 | -79.8 | -177.5 | 13.7 | 24.6 | 38.3 | | | | | | n.m. | n.m. | n.m. | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Changes in other assets and liabilities | 40.0 | -18.3 | 21.7 | 19.2 | 40.9 | 21.3 | 40.6 | 62.3 | -45.0 | 82.1 | 37.1 | | | | | | n.m. | n.m. | 156.3% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Neutralization of gain/loss on disposal of fixed assets and other disposals | 32.6 | -264.8 | -232.2 | 180.0 | -52.3 | -256.7 | -76.7 | -308.9 | -224.0 | -466.6 | -690.5 | | | | | | n.m. | 76.2% | 197.4% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Other non-cash income and expenses | -7.9 | -1.2 | -9.2 | 0.0 | -9.2 | 7.1 | 7.0 | -2.1 | 10.0 | -5.4 | 4.6 | | | | | | n.m. | 332.2% | n.m. | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Operating Cash Flow | 1,035.1 | 861.2 | 1,896.3 | 1,458.3 | 3,354.6 | 1,231.5 | 2,689.8 | 4,586.1 | 555.8 | 566.9 | 1,122.7 | | | | | | -46.3% | -34.2% | -40.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| thereof: from discontinued operations | | | | | | | | | 0.0 | 0.0 | 0.0 | | | | | | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. |
| Payments for investments in intangible assets | -248.0 | -34.9 | -282.9 | -97.7 | -380.6 | -100.9 | -198.6 | -481.5 | -37.4 | -144.4 | -181.9 | | | | | | -84.9% | 314.4% | -35.7% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Payments from the disposal of intangible assets | 5.9 | 1.9 | 7.8 | 0.9 | 8.7 | 9.0 | 9.8 | 17.6 | 2.1 | 4.6 | 6.7 | | | | | | -64.0% | 141.0% | -14.2% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Payments for investments in property, plant and equipment | -522.8 | -315.7 | -838.5 | -455.7 | -1,294.2 | -407.4 | -863.1 | -1,701.6 | -486.6 | -300.3 | -786.9 | | | | | | -6.9% | -4.9% | -6.2% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Payments from the disposal of property, plant and equipment | 10.7 | 6.0 | 16.7 | 18.1 | 34.8 | -8.2 | 10.0 | 26.6 | 5.2 | 2.0 | 7.2 | | | | | | -51.4% | -66.0% | -56.6% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Payments for investments in other assets | -287.5 | -42.3 | -329.8 | -1,503.9 | -1,833.7 | -417.3 | -1,921.2 | -2,251.0 | -329.6 | -322.4 | -652.0 | | | | | | 14.7% | 662.1% | 97.7% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Payments from the disposal of other assets | 346.7 | 354.5 | 701.1 | 894.0 | 1,595.2 | 511.9 | 1,405.9 | 2,107.0 | 427.4 | 620.3 | 1,047.7 | | | | | | 23.3% | 75.0% | 49.4% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Payments for acquisitions less acquired cash and cash equivalents (net) | | 0.0 | 0.0 | -553.9 | -553.9 | -219.9 | -773.8 | -773.8 | -0.2 | -2.4 | -2.7 | | | | | | n.m. | n.m. | n.m. | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Payments from divestments | 6.3 | 0.1 | 6.3 | 0.0 | 6.3 | 0.5 | 0.5 | 6.8 | 0.0 | -0.1 | -0.1 | | | | | | -99.5% | n.m. | n.m. | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Investing Cash Flow | -688.7 | -30.5 | -719.2 | -1,698.2 | -2,417.4 | -632.4 | -2,330.6 | -3,049.8 | -419.1 | -142.8 | -561.9 | | | | | | -39.2% | 368.7% | -21.9% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| thereof: from discontinued operations | | | | | | | | | 0.0 | 0.0 | 0.0 | | | | | | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. |
| Dividend payments to Merck KGaA shareholders | | -284.3 | -284.3 | | -284.3 | | | -284.3 | 0.0 | -284.3 | -284.3 | | | | | | n.m. | 0.0% | 0.0% | n.m. | -100.0% | n.m. | n.m. | -100.0% |
| Dividend payments to non-controlling interests | 0.0 | -9.1 | -9.1 | 0.0 | -9.1 | 0.0 | 0.0 | -9.1 | 0.0 | -9.0 | -9.0 | | | | | | n.m. | -1.2% | -1.2% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Profit withdrawal by E.Merck KG | -52.3 | -694.3 | -746.6 | | -746.6 | | | -746.6 | -46.0 | -709.1 | -755.1 | | | | | | -12.1% | 2.1% | 1.1% | n.m. | -100.0% | n.m. | n.m. | -100.0% |
| Changes in financial liabilities to E. Merck KG and E. Merck Beteiligungen KG | -26.9 | 556.4 | 529.5 | 16.8 | 546.3 | -315.7 | -298.9 | 230.6 | -3.2 | 698.8 | 695.6 | | | | | | -88.3% | 25.6% | 31.4% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Other changes in net equity | -0.1 | 0.0 | -0.1 | 0.0 | -0.1 | 0.5 | 0.5 | 0.5 | -0.3 | 0.3 | 0.0 | | | | | | 330.7% | >1.000% | -96.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Changes in current and non-current financial liabilities | -27.6 | 71.5 | 43.9 | 710.6 | 754.5 | -930.6 | -220.0 | -176.2 | -1,559.8 | 46.1 | -1,513.7 | | | | | | >1.000% | -28.7% | n.m. | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Other changes from financing activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | -0.1 | 0.1 | -0.1 | 0.0 | | | | | | >1.000% | n.m. | >1.000% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Financing Cash Flow | -106.9 | -359.8 | -466.8 | 727.4 | 260.6 | -1,245.8 | -518.4 | -985.2 | -1,609.2 | -257.3 | -1,866.5 | | | | | | >1.000% | -29.8% | 298.8% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| thereof: from discontinued operations | | | | | | | | | 0.0 | 0.0 | 0.0 | | | | | | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. |
| Changes in cash and cash equivalents | 239.5 | 470.9 | 710.4 | 487.5 | 1,197.9 | -646.8 | -159.3 | 551.1 | -1,472.5 | 166.8 | -1,305.7 | | | | | | n.m. | -63.5% | n.m. | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Changes in cash and cash equivalents due to currency translation | -2.0 | -5.4 | -7.4 | -11.5 | -18.9 | 2.8 | -8.8 | -16.1 | -39.8 | -5.6 | -45.3 | | | | | | >1.000% | 3.3% | 515.7% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Cash and cash equivalents as of January 1st | 1,982.0 | 0.0 | 1,982.0 | | 1,982.0 | 0.0 | 0.0 | 1,982.0 | 2,517.0 | 0.0 | 2,517.0 | | | | | | 27.0% | -100.0% | 27.0% | n.m. | -100.0% | -100.0% | -100.0% | -100.0% |
| Cash and cash equivalents | 2,219.6 | 465.5 | 2,695.0 | 476.0 | 3,161.0 | -644.0 | -168.0 | 2,517.0 | 1,004.7 | 161.2 | 1,166.0 | | | | | | -54.7% | -65.4% | -56.6% | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |
| Changes in cash and cash equivalents due to change in scope of consolidation | | | | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | | | | n.m. | n.m. | n.m. | -100.0% | -100.0% | -100.0% | -100.0% | -100.0% |

Due to rounding the sum of individual values may not add up to totals presented.

Balance Sheet Merck KGaA, Darmstadt, Germany
Group

| € million | 2024 | | | | 2025 | | | | Classification: CONFIDENTIAL | | | | Shares of Totals | | | |
|-------------------------------------------------------------------|-----------------|-----------------|-----------------|----------------------|-----------------|-----------------|---------|---------|------------------------------|---------|---------|---------|------------------|---------|---------|---------|
| | 31. Mrz | 30. Jun | 30. Sep | 31. Dez ¹ | 31. Mrz | 30. Jun | 30. Sep | 31. Dez | 31. Mrz | 30. Jun | 30. Sep | 31. Dez | 31. Mrz | 30. Jun | 30. Sep | 31. Dez |
| Non-current assets | 36,680.9 | 36,828.4 | 36,213.3 | 36,145.5 | 36,960.6 | 35,155.6 | | | 74.1% | 73.8% | 72.2% | 73.9% | 74.9% | 74.2% | | |
| Goodwill | 18,180.8 | 18,320.6 | 18,092.8 | 19,106.6 | 18,574.6 | 17,341.0 | | | 36.7% | 36.7% | 35.1% | 37.0% | 37.6% | 36.6% | | |
| Other intangible asset: | 6,480.6 | 6,208.0 | 5,845.1 | 6,351.3 | 5,981.4 | 5,584.0 | | | 13.1% | 12.4% | 11.7% | 12.3% | 12.1% | 11.8% | | |
| Property, plant and equipment | 9,214.4 | 9,433.0 | 9,414.7 | 10,025.0 | 9,854.0 | 9,662.7 | | | 18.6% | 18.9% | 18.8% | 19.4% | 20.0% | 20.4% | | |
| Investments accounted for using the equity metho | 2.9 | 2.9 | 2.8 | 3.0 | 2.9 | 2.7 | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | |
| Other non-current receivable: | 26.9 | 24.9 | 24.6 | 27.3 | 27.6 | 30.5 | | | 0.1% | 0.0% | 0.0% | 0.1% | 0.1% | 0.1% | | |
| Other non-current financial asset: | 1,067.7 | 1,062.2 | 1,090.1 | 1,172.3 | 1,044.8 | 1,031.1 | | | 2.2% | 2.1% | 2.2% | 2.3% | 2.1% | 2.2% | | |
| Other non-current non-financial asset: | 138.1 | 133.6 | 129.3 | 133.6 | 105.9 | 107.6 | | | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.2% | | |
| Non-current income tax receivable: | 9.1 | 10.3 | 9.0 | 8.6 | 8.3 | 8.3 | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | |
| Deferred tax assets: | 1,560.4 | 1,632.8 | 1,605.8 | 1,317.7 | 1,360.3 | 1,387.6 | | | 3.2% | 3.3% | 3.2% | 2.6% | 2.8% | 2.9% | | |
| Current assets | 12,823.5 | 13,046.6 | 13,928.6 | 13,450.4 | 12,412.1 | 12,195.9 | | | 25.9% | 26.2% | 27.8% | 26.1% | 25.1% | 25.8% | | |
| Inventories | 4,716.4 | 4,714.4 | 4,404.8 | 4,464.2 | 4,513.2 | 4,468.0 | | | 9.5% | 9.5% | 8.8% | 8.7% | 9.1% | 9.4% | | |
| Trade and other current receivable | 4,147.1 | 4,263.0 | 3,969.0 | 3,946.5 | 4,339.0 | 4,231.2 | | | 8.4% | 8.5% | 8.0% | 7.6% | 8.8% | 8.9% | | |
| Contract assets | 99.1 | 123.2 | 120.0 | 131.5 | 133.2 | 130.8 | | | 0.2% | 0.2% | 0.2% | 0.3% | 0.3% | 0.3% | | |
| Other current financial assets | 264.1 | 129.7 | 699.2 | 641.6 | 615.0 | 407.4 | | | 0.5% | 0.3% | 1.4% | 1.2% | 1.2% | 0.9% | | |
| Other current non-financial assets: | 942.4 | 672.5 | 622.0 | 621.2 | 701.7 | 692.5 | | | 1.9% | 1.3% | 1.2% | 1.2% | 1.4% | 1.5% | | |
| Current income tax receivable: | 434.8 | 458.9 | 355.8 | 511.7 | 505.9 | 515.6 | | | 0.9% | 0.9% | 0.7% | 1.0% | 1.0% | 1.1% | | |
| Cash and cash equivalent: | 2,219.6 | 2,685.0 | 3,161.0 | 2,517.0 | 1,004.7 | 1,166.0 | | | 4.5% | 5.4% | 6.3% | 4.9% | 2.0% | 2.5% | | |
| Assets held for sale | 0.0 | 0.0 | 577.9 | 596.7 | 599.3 | 584.4 | | | 0.0% | 0.0% | 1.2% | 1.2% | 1.2% | 1.2% | | |
| Total assets | 49,504.4 | 49,875.0 | 50,141.9 | 51,595.9 | 49,372.7 | 47,351.5 | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | |
| Total equity | 28,074.2 | 28,616.0 | 28,393.4 | 29,989.1 | 29,897.3 | 28,328.6 | | | 56.7% | 57.4% | 56.6% | 58.1% | 60.6% | 59.8% | | |
| Equity capita | 565.2 | 565.2 | 565.2 | 565.2 | 565.2 | 565.2 | | | 1.1% | 1.1% | 1.1% | 1.1% | 1.1% | 1.2% | | |
| Capital reserves | 3,813.7 | 3,813.7 | 3,813.7 | 3,813.7 | 3,813.7 | 3,813.7 | | | 7.7% | 7.6% | 7.6% | 7.4% | 7.7% | 8.1% | | |
| Retained earnings | 21,031.1 | 21,378.7 | 22,145.5 | 22,087.3 | 22,979.5 | 23,345.0 | | | 42.5% | 42.9% | 44.2% | 42.8% | 46.5% | 49.3% | | |
| Gain/losses recognized in equity | 2,585.9 | 2,791.6 | 1,798.9 | 3,447.7 | 2,464.0 | 534.3 | | | 5.2% | 5.6% | 3.6% | 6.7% | 5.0% | 1.1% | | |
| Non-controlling interest | 78.2 | 66.8 | 70.1 | 75.3 | 74.7 | 70.4 | | | 0.2% | 0.1% | 0.1% | 0.1% | 0.2% | 0.1% | | |
| Non-current liabilities | 11,491.1 | 11,327.6 | 11,286.0 | 10,311.6 | 9,973.4 | 9,164.2 | | | 23.2% | 22.7% | 22.5% | 20.0% | 20.2% | 19.4% | | |
| Non-current provisions for employee benefits: | 2,132.9 | 2,064.2 | 2,068.0 | 1,955.7 | 1,749.0 | 1,712.5 | | | 4.3% | 4.1% | 4.1% | 3.8% | 3.5% | 3.6% | | |
| Other non-current provisions: | 262.7 | 240.3 | 240.1 | 256.8 | 243.2 | 255.3 | | | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | 0.5% | | |
| Non-current financial deb | 7,822.5 | 7,822.0 | 7,884.2 | 6,997.0 | 6,964.1 | 6,299.2 | | | 15.8% | 15.7% | 15.7% | 13.6% | 14.1% | 13.3% | | |
| Other non-current financial liability: | 150.5 | 130.7 | 135.2 | 143.9 | 134.6 | 120.3 | | | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | | |
| Other non-current non-financial liability: | 16.3 | 12.1 | 11.2 | 12.5 | 11.6 | 10.7 | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | |
| Non-current income tax liability: | 39.4 | 39.5 | 39.2 | 36.4 | 36.2 | 35.9 | | | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | | |
| Deferred tax liability: | 1,066.7 | 1,018.7 | 907.0 | 909.3 | 834.7 | 730.3 | | | 2.2% | 2.0% | 1.8% | 1.8% | 1.7% | 1.5% | | |
| Current liabilities | 9,939.1 | 9,931.4 | 10,462.5 | 11,295.2 | 9,502.0 | 9,858.7 | | | 20.1% | 19.9% | 20.9% | 21.9% | 19.2% | 20.8% | | |
| Current provisions for employee benefit | 81.3 | 73.0 | 71.2 | 65.6 | 56.7 | 67.7 | | | 0.2% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | | |
| Other current provisions: | 594.0 | 597.3 | 592.9 | 504.7 | 453.3 | 485.2 | | | 1.2% | 1.2% | 1.2% | 1.0% | 0.9% | 1.1% | | |
| Current financial deb | 2,130.5 | 2,927.5 | 3,508.5 | 3,304.0 | 1,733.9 | 3,103.1 | | | 4.3% | 5.9% | 7.0% | 6.4% | 3.5% | 6.6% | | |
| Other current financial liability: | 994.4 | 276.3 | 199.1 | 1,031.5 | 914.4 | 237.3 | | | 2.0% | 0.6% | 0.4% | 2.0% | 1.9% | 0.5% | | |
| Trade and other current payable | 2,086.0 | 2,121.6 | 1,950.0 | 2,274.5 | 2,092.3 | 1,960.4 | | | 4.2% | 4.3% | 3.9% | 4.4% | 4.2% | 4.1% | | |
| Refund liabilities: | 880.9 | 890.5 | 853.5 | 868.9 | 914.2 | 929.3 | | | 1.8% | 1.8% | 1.7% | 1.7% | 1.9% | 2.0% | | |
| Current income tax liability: | 1,564.9 | 1,659.7 | 1,672.7 | 1,527.5 | 1,605.7 | 1,591.0 | | | 3.2% | 3.3% | 3.3% | 3.0% | 3.3% | 3.4% | | |
| Other current non-financial liability: | 1,607.1 | 1,385.4 | 1,517.8 | 1,561.8 | 1,579.2 | 1,321.0 | | | 3.2% | 2.8% | 3.0% | 3.0% | 3.2% | 2.8% | | |
| Liabilities included in disposal groups classified as held for sa | 0.0 | 0.0 | 96.7 | 156.8 | 152.3 | 163.7 | | | 0.0% | 0.0% | 0.2% | 0.3% | 0.3% | 0.3% | | |
| Total liabilities and stockholders' equity | 49,504.4 | 49,875.0 | 50,141.9 | 51,595.9 | 49,372.7 | 47,351.5 | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | | |

| | 31. Mrz | 30. Jun | 30. Sep | 31. Dez | 31. Mrz | 30. Jun | 30. Sep | 31. Dez | 31. Mrz | 30. Jun | 30. Sep | 31. Dez | 31. Mrz | 30. Jun | 30. Sep | 31. Dez |
|------------------------------------------------------------|---------|----------|----------|----------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| Financial debt | 9,953.0 | 10,749.5 | 11,392.7 | 10,301.0 | 8,698.0 | 9,402.3 | | | 20.1% | 21.6% | 22.7% | 20.0% | 17.6% | 19.9% | | |
| Net financial debt | 7,497.9 | 7,949.6 | 7,552.9 | 7,155.1 | 7,121.1 | 7,973.0 | | | 15.1% | 15.9% | 15.1% | 13.9% | 14.4% | 16.8% | | |
| Additions to Property, plant and equipment (excl. Leasing) | 305.3 | 695.0 | 1,122.7 | 1,734.9 | 270.1 | 609.1 | | | n.m. | n.m. | n.m. | n.m. | n.m. | n.m. | | |

Due to rounding the sum of individual values may not add up to totals presented

¹ Figures are year-to-date figures from January 1st until stated end date.

² Previous-year figures have been adjusted owing to the finalization of the purchase price allocation in connection with the acquisitions of Mirus Bio LLC, USA, Unity-SC SAS, France, as well as Hub Organoids Holding B.V., Netherlands.